Elizabeth Tito, MD
Surgery · Santa Rosa, CANPI 1629092309
Payments from drug & device makers
Across 166 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$668
- AstraZeneca$536
- Regeneron Healthcare Solutions, Inc.$257
- Daiichi Sankyo Inc.$203
- Johnson & Johnson$200
- Seagen Inc.$194
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,924100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $668 |
| AstraZeneca(2 entities) | 23 | $536 |
| Regeneron Healthcare Solutions, Inc. | 8 | $257 |
| Daiichi Sankyo Inc. | 10 | $203 |
| Johnson & Johnson | 8 | $200 |
| Seagen Inc. | 8 | $194 |
| Pfizer | 5 | $141 |
| Bristol Myers Squibb | 6 | $139 |
| Eisai Inc. | 6 | $138 |
| GSK | 5 | $136 |
| Exelixis Inc. | 5 | $118 |
| Merck | 7 | $112 |
| Novartis | 5 | $106 |
| Servier Pharmaceuticals LLC | 5 | $96 |
| Lilly USA, LLC | 4 | $77 |
| Beigene USA, Inc. | 3 | $76 |
| Incyte Corporation | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Foundation Medicine, Inc. | 2 | $61 |
| Taiho Oncology, Inc. | 3 | $60 |
| Rigel Pharmaceuticals, Inc. | 2 | $47 |
| Gilead | 2 | $47 |
| Genentech USA, Inc. | 2 | $39 |
| Springworks Therapeutics, Inc. | 1 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Invivyd Inc | 1 | $33 |
| Tempus AI, Inc | 1 | $29 |
| GE HealthCare | 2 | $26 |
| Bayer | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Morphosys, US Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Octapharma USA, Inc. | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$124
How this compares
$3,924 in reported general payments places this provider in the 55th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgery in Santa Rosa
- Timothy ChuterSan Francisco$8.9M
- Peter StockSan Francisco$6.5M
- Santiago HorganSan Diego$2.8M
- Kenneth DeckLaguna Hills$2.4M
- Daniel RiskinSan Jose$2.2M
- Michael DemeureNewport Beach$1.7M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.